PULSE BIOSCIENCES, INC.

For the period ended Sep 30, 2026. Filed Nov 5, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 5, 2026

PLSE$55.12-5.2%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Stockholders’ Equity

(In thousands, except share amounts)

Accumulated
Additional · Other · Total
Common Stock · Paid-in · Comprehensive · Accumulated · Stockholders’
	Shares	Amount	Capital	Loss	Deficit	Equity
Balance—December 31, 2025	67,839,689	$68	$543,869	$—	$(463,281)	$80,656
Issuance of common stock upon exercise of warrants, net of issuance costs	9,321	—	100	—	—	100
Issuance of common stock upon exercise of stock options	339,840	—	1,746	—	—	1,746
Issuance of common stock under employee stock purchase plan	36,217	—	465	—	—	465
Stock-based compensation expense	—	—	1,912	—	—	1,912
Net loss	—	—	—	—	(18,581)	(18,581)
Balance—March 31, 2026	68,225,067	68	548,092	—	(481,862)	66,298
Issuance of common stock under at-the-market offering program, net of issuance costs	1,919,821	2	46,848	—	—	46,850
Issuance of common stock upon exercise of warrants, net of issuance costs	43,243	—	476	—	—	476
Issuance of common stock upon exercise of stock options	611,831	1	5,559	—	—	5,560
Stock-based compensation expense	—	—	4,973	—	—	4,973
Net loss	—	—	—	—	(24,657)	(24,657)
Balance—June 30, 2026	70,799,962	71	605,948	—	(506,519)	99,500
Issuance of common stock under at-the-market offering program, net of issuance costs	2,097,180	2	95,808	—	—	95,810
Issuance of common stock upon exercise of stock options	267,464	—	4,381	—	—	4,381
Issuance of common stock upon exercise of warrants, net of issuance costs	124,896	—	1,369	—	—	1,369
Issuance of common stock under employee stock purchase plan	25,295	—	335	—	—	335
Stock-based compensation expense	—	—	5,312	—	—	5,312
Unrealized loss on marketable securities	—	—	—	(83)	—	(83)
Net loss	—	—	—	—	(23,051)	(23,051)
Balance—September 30, 2026	73,314,797	$73	$713,153	$(83)	$(529,570)	$183,573

PULSE BIOSCIENCES, INC.

Condensed Consolidated Statements of Stockholders’** Equity**

(In thousands, except share amounts)

Accumulated
Additional · Other · Total
Common Stock · Paid-in · Comprehensive · Accumulated · Stockholders’
	Shares	Amount	Capital	Loss	Deficit	Equity
Balance, December 31, 2024	65,925,503	$66	$505,296	$—	$(390,500)	$114,862
Issuance of common stock upon exercise of warrants, net of issuance costs	1,271,453	1	13,971	—	—	13,972
Issuance of common stock upon exercise of stock options	51,000	—	380	—	—	380
Issuance of common stock under employee stock purchase plan	25,844	—	352	—	—	352
Stock-based compensation expense	—	—	5,681	—	—	5,681
Net loss	—	—	—	—	(16,795)	(16,795)
Balance—March 31, 2025	67,273,800	67	525,680	—	(407,295)	118,452
Issuance of common stock upon exercise of warrants, net of issuance costs	332	—	2	—	—	2
Issuance of common stock upon exercise of stock options	3,750	—	12	—	—	12
Stock-based compensation expense	—	—	5,189	—	—	5,189
Net loss	—	—	—	—	(19,168)	(19,168)
Balance—June 30, 2025	67,277,882	67	530,883	—	(426,463)	104,487
Issuance of common stock upon exercise of stock options	438,681	1	1,707	—	—	1,708
Issuance of common stock under employee stock purchase plan	18,752	—	241	—	—	241
Issuance of common stock upon exercise of warrants, net of issuance costs	2,453	—	25	—	—	25
Stock-based compensation expense	—	—	5,618	—	—	5,618
Net loss	—	—	—	—	(19,385)	(19,385)
Balance—September 30, 2025	67,737,768	$68	$538,474	$—	$(445,848)	$92,694

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.